Jazz Pharmaceuticals vs Regeneron Pharmaceuticals
JAZZ and REGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How JAZZ and REGN compare
Regeneron Pharmaceuticals is the larger company, worth 6.8 times as much as Jazz Pharmaceuticals ($95.5B against $14.0B).
On earnings, Jazz Pharmaceuticals is cheaper: it trades at 14.8× trailing earnings, against 20.5× for Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals grew revenue faster over the last twelve months (18.6% versus 12.6% for Jazz Pharmaceuticals).
Regeneron Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 28.5% compared with 20.4% at Jazz Pharmaceuticals.
Regeneron Pharmaceuticals pays a dividend yielding 0.40%; Jazz Pharmaceuticals does not pay one.
Regeneron Pharmaceuticals scores higher on the StockData Score (17 against 11 for Jazz Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | JAZZ | REGN |
|---|---|---|
| Size and price | ||
| Market cap | $14.0B | $95.5B |
| Share price | $215.98 | $927.89 |
| Change, 1 year | 59.1% | 42.1% |
| Change, 5 years | 59.9% | 51.7% |
| Beta (5Y) | 0.55 | 0.64 |
| Employees | 2,890 | 15K |
| StockData Score | ||
| Total score | 11 | 17 (better) |
| Valuation score | 4 (better) | 1 |
| Growth score | 1 | 3 (better) |
| Performance score | 4 | 4 |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | 14.8× (better) | 20.5× |
| P/S | 3.0× (better) | 5.7× |
| P/B | 2.9× | 2.9× (better) |
| EV/EBITDA | 18.0× | 16.4× (better) |
| P/FCF | 8.8× (better) | 25.0× |
| PEG | – | 7.41 |
| FCF yield | 11.4% (better) | 4.0% |
| Fair value | $254.92 | $851.58 |
| Margin of safety | 15.3% (better) | −9.0% |
| Growth | ||
| Revenue growth (TTM) | 12.6% | 18.6% (better) |
| Revenue growth, 5Y average | 12.5% (better) | 11.0% |
| Net income growth (TTM) | – | 5.2% |
| EPS growth (TTM) | – | 8.4% |
| EPS growth, 5Y average | – | 6.3% |
| Profitability | ||
| Operating margin | 19.5% | 28.8% (better) |
| Net margin | 20.4% | 28.5% (better) |
| FCF margin | 34.6% (better) | 22.6% |
| Return on equity | 22.1% (better) | 14.9% |
| Return on invested capital | 12.1% | 16.3% (better) |
| Financial health | ||
| Debt / equity | 0.91 | 0.06 (better) |
| Net debt / EBITDA | 2.40 (better) | −1.36 |
| Interest coverage | – | 104× |
| Current ratio | 1.78 | 3.35 (better) |
| Altman Z-score | 2.35 | 7.64 (better) |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.40% |
| Payout ratio | – | 8.0% |
| Buyback yield | – | 2.1% |
| Shareholder yield | 0.00% | 2.5% (better) |
| Ownership | ||
| Held by institutions | 99.2% | 89.0% |
| Held by insiders | 3.4% | 3.8% |
| Insider net buying, 12 months | −$68.0M | −$8.7M (better) |
| Superinvestors holding | 1 | 1 |
| Short interest, % of float | 8.7% | 2.2% |
Go deeper
- JAZZ stock overview
- JAZZ income statement
- JAZZ valuation and score
- REGN stock overview
- REGN income statement
- REGN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.